chr2-165747846-T-TA

Variant summary

Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BS1_SupportingBS2

The NM_004482.4(GALNT3):​c.*934dupT variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00334 in 170,736 control chromosomes in the GnomAD database, including 5 homozygotes. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.0035 ( 5 hom., cov: 32)
Exomes 𝑓: 0.0022 ( 0 hom. )

Consequence

GALNT3
NM_004482.4 3_prime_UTR

Scores

Not classified

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.153

Publications

0 publications found
Variant links:
Genes affected
GALNT3 (HGNC:4125): (polypeptide N-acetylgalactosaminyltransferase 3) This gene encodes UDP-GalNAc transferase 3, a member of the GalNAc-transferases family. This family transfers an N-acetyl galactosamine to the hydroxyl group of a serine or threonine residue in the first step of O-linked oligosaccharide biosynthesis. Individual GalNAc-transferases have distinct activities and initiation of O-glycosylation is regulated by a repertoire of GalNAc-transferases. The protein encoded by this gene is highly homologous to other family members, however the enzymes have different substrate specificities. [provided by RefSeq, Jul 2008]
GALNT3 Gene-Disease associations (from GenCC):
  • tumoral calcinosis, hyperphosphatemic, familial, 1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae)
  • tumoral calcinosis, hyperphosphatemic, familial, 1
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -5 ACMG points.

BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.00348 (529/152064) while in subpopulation AMR AF = 0.00964 (147/15254). AF 95% confidence interval is 0.00837. There are 5 homozygotes in GnomAd4. There are 250 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 5 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GALNT3NM_004482.4 linkc.*934dupT 3_prime_UTR_variant Exon 11 of 11 ENST00000392701.8 NP_004473.2 Q14435-1
GALNT3XM_005246449.2 linkc.*934dupT 3_prime_UTR_variant Exon 11 of 11 XP_005246506.1 Q14435-1
GALNT3XM_011510929.2 linkc.*934dupT 3_prime_UTR_variant Exon 11 of 11 XP_011509231.1 Q14435-1
GALNT3XM_017003770.2 linkc.*934dupT 3_prime_UTR_variant Exon 11 of 11 XP_016859259.1 Q14435-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GALNT3ENST00000392701.8 linkc.*934dupT 3_prime_UTR_variant Exon 11 of 11 1 NM_004482.4 ENSP00000376465.3 Q14435-1
GALNT3ENST00000409882.5 linkc.*934dupT 3_prime_UTR_variant Exon 8 of 8 1 ENSP00000386955.1 E7EUL0
ENSG00000307262ENST00000824811.1 linkn.130+930dupA intron_variant Intron 1 of 1

Frequencies

GnomAD3 genomes
AF:
0.00348
AC:
529
AN:
151946
Hom.:
5
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00681
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00965
Gnomad ASJ
AF:
0.00144
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000946
Gnomad MID
AF:
0.0222
Gnomad NFE
AF:
0.00107
Gnomad OTH
AF:
0.00672
GnomAD4 exome
AF:
0.00220
AC:
41
AN:
18672
Hom.:
0
Cov.:
0
AF XY:
0.00143
AC XY:
12
AN XY:
8420
show subpopulations
African (AFR)
AF:
0.0109
AC:
7
AN:
640
American (AMR)
AF:
0.00980
AC:
4
AN:
408
Ashkenazi Jewish (ASJ)
AF:
0.00192
AC:
2
AN:
1044
East Asian (EAS)
AF:
0.00
AC:
0
AN:
4238
South Asian (SAS)
AF:
0.00
AC:
0
AN:
156
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
8
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
102
European-Non Finnish (NFE)
AF:
0.00191
AC:
20
AN:
10496
Other (OTH)
AF:
0.00506
AC:
8
AN:
1580
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.509
Heterozygous variant carriers
0
2
4
6
8
10
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome
AF:
0.00348
AC:
529
AN:
152064
Hom.:
5
Cov.:
32
AF XY:
0.00336
AC XY:
250
AN XY:
74338
show subpopulations
African (AFR)
AF:
0.00681
AC:
283
AN:
41528
American (AMR)
AF:
0.00964
AC:
147
AN:
15254
Ashkenazi Jewish (ASJ)
AF:
0.00144
AC:
5
AN:
3464
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5180
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4818
European-Finnish (FIN)
AF:
0.0000946
AC:
1
AN:
10572
Middle Eastern (MID)
AF:
0.0238
AC:
7
AN:
294
European-Non Finnish (NFE)
AF:
0.00106
AC:
72
AN:
67936
Other (OTH)
AF:
0.00665
AC:
14
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
26
52
77
103
129
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000650
Hom.:
0
Bravo
AF:
0.00480

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome Uncertain:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
0.15

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs144647329; hg19: chr2-166604356; API